Pennsylvania-based pharmaceutical company Endo Health Solutions has agreed to pay $193 million to settle claims that it engaged in illegal off-label marketing of its pain relief medication, Lidoderm.
The company will pay $172 million to several states and the federal government to resolve whistleblower claims brought in the Eastern District of Pennsylvania and it will pay $21 million in criminal forfeiture and fines under a deferred prosecution agreement with the U.S. Attorney’s Office for the Northern District of New York, according to releases from the U.S. Department of Justice, the U.S. Attorney’s Office for the Eastern District of Pennsylvania and Endo Health Solutions.
